Research Article
Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study
Table 2
Babies’ characteristics during a total of 5 seasons.
| | Variables | Total babies (N = 925) | <32 weeks (N = 410) | 32–35 weeks (N = 515) | value |
| | Gender, N (%) | | | | | | Female | 501 (54.10%) | 245 (59.80%) | 256 (49.70%) | 0.38 | | Male | 424 (46.60%) | 165 (40.20%) | 259 (50.2%) | | | Gestational age in weeks, median (IQR) | 30.28 (4.1) | 27.52 (4.3) | 33.04 (4.2) | 0.35 | | Female | 30.60 (3.8) | 27.90 (4.1) | 33.3 (3.95) | | | Male | 29.96 (4.4) | 27.12 (4.5) | 32.8 (4.45) | | | Birth weight, g median (IQR) | 1460.6 (410.2) | 1100.8 (383.8) | 1820.5 (397) | 0.42 | | Female | 1482.5 (398.1) | 1116.5 (365.1) | 1848.5 (431) | | | Male | 1438.7 (422.3) | 1084 (402.5) | 1792 (442) | | | Age at enrollment, N (%) | | | 390 (75.70%) | 0.42 | | ≤3 months | 589 (63.60%) | 199 (48.50%) | 50 (9.70%) | | | 4–6 months | 168 (18.10%) | 118 (22.90%) | 29 (5.60%) | | | 7–12 months | 98 (10.50%) | 69 (16.80%) | 7 (1.30%) | | | >12 months | 70 (7.50%) | 63 (15.30%) | | | | Multiple birth, N (%) | 153 (16.50%) | 105 (25.60%) | 48 (9.30%) | 0.15 | | Chronic lungs disease, N (%) | 180 (19.40%) | 122 (29.70%) | 58 (11.20%) | 0.09 | | Congenital heart disease, N (%) | 37 (4%) | 30 (7.30%) | 7 (1.30%) | 0.04 | | Presence of siblings, N (%) | 698 (75.40%) | 333 (81.20%) | 365 (70.80%) | 0.71 | | Siblings in school, N (%) | 389 (42%) | 140 (34.10%) | 249 (48.30%) | 0.23 | | Parental asthma, N (%) | 135 (14.50%) | 76 (18.50%) | 59 (11.40%) | 0.85 | | Sibling history of asthma, N (%) | 78 (8.43%) | 44 (10.73%) | 34 (6.60%) | 0.62 | | Mother’s age, years median (IQR) | 30.5 (9) | 31.6 (9.4) | 29.4 (8.6) | 0.36 | | Childcare center exposure, N (%) | 65 (7%) | 49 (11.90%) | 16 (3.10%) | 0.18 | | Smoke exposure, N (%) | 307 (33.10%) | 157 (38.20%) | 150 (29.10%) | 0.29 |
|
|
RSV, respiratory syncytial virus; IQR, interquartile range.
|
